1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Boon in the Fight Against Prostate Cancer

ZYTIGA (abiraterone acetate) Receives FDA Approval

 
 
PCEC Logo BLUE no ribbon
PCEC Logo BLUE no ribbon
PRLog - May 4, 2011 - DENVER – The U.S. Food and Drug Administration approved ZYTIGA today, a once-daily, oral medication used in the treatment of certain men with advanced prostate cancer.

Prostate cancer is the most prevalent form of cancer among American males. More than 220,000 will be diagnosed with prostate cancer this year and 32,000 men will die from the disease.   Young men aged 35 to 44 have been found to have the highest percentage of advanced (metastatic) disease and risk of death.  In addition, African American men are 1.6 times as likely to be diagnosed with prostate cancer and 2.4 times as likely to die of this disease.

For over a decade, limited treatments have been available for men with advanced prostate cancer.  New therapies like ZYTIGA, not only provide a significant improvement in survival and quality of life for patients but also provide hope to men and their families.

“I am thrilled to have another arrow in our quiver to manage prostate cancer,” states E. David Crawford, MD, Chairman of the Prostate Conditions Education Council.  “ I am excited for patients as we continue to see advancements in all aspects of the disease from early detection and staging to improved surgery techniques and across all treatment options in our fight against prostate cancer.”

Phase 3 clinical trials with ZYTIGA and prednisone showed a significant increase in median survival compared with a placebo and prednisone.  Clinical trail data show a 35% reduction in the risk of death and up to a 4.6-month median survival advantage.  ZYTIGA is indicated, in combination with prednisone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel.

“We hope the recent advancements in prostate cancer treatment options will not only encourage advanced prostate cancer patients to have meaningful conversations with their physicians about treatment options, but will also encourage all men to take an active role in their health and engage in discussion about the early detection of the disease,” states Wendy Poage, President of the Prostate Conditions Education Council.

For more information, contact the Prostate Conditions Education Council at 866-4PROST8 (866-477-6788) or visit our website at www.prostateconditions.org.

# # #

About the Prostate Conditions Education Council
A national organization committed to men’s health, the Prostate Conditions Education Council (PCEC) - is the nation’s leading resource for information on prostate health. The PCEC is dedicated to saving lives through awareness and the education of men, the women in their lives, as well as the medical community about prostate cancer prevalence, the importance of early detection, and available treatment options, as well as other men’s health issues. The Council – comprised of a consortium of leading physicians, health educators, scientists and prostate cancer advocates – aims to conduct nation wide screenings for men and perform research that will aid in the detection and treatment of prostate conditions. More information is available at www.prostateconditions.org.

Photo:
http://www.prlog.org/11472785/1

--- End ---

Click to Share

Contact Email:
***@prostateconditions.org Email Verified
Source:Prostate Conditions Education Council
Phone:3033164685
Zip:80112
City/Town:Centennial - Colorado - United States
Industry:Health, Medical, Government
Tags:prostate cancer, prostate cancer treatment, prostate cancer therapy, Prostate Cancer Drugs
Shortcut:prlog.org/11472785
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share